Aptorum Group Limited - Class A Ordinary Shares (APM): Price and Financial Metrics
APM Price/Volume Stats
| Current price | $5.59 | 52-week high | $17.49 |
| Prev. close | $5.56 | 52-week low | $1.35 |
| Day low | $5.55 | Volume | 4,824 |
| Day high | $5.68 | Avg. volume | 1,923,766 |
| 50-day MA | $6.01 | Dividend yield | N/A |
| 200-day MA | $2.99 | Market Cap | 19.97M |
APM Stock Price Chart Interactive Chart >
Aptorum Group Limited - Class A Ordinary Shares (APM) Company Bio
Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.
Latest APM News From Around the Web
Below are the latest news stories about APTORUM GROUP LTD that investors may wish to consider to help them evaluate APM as an investment opportunity.
APM Stock: Is It Worth Investing In APM?Aptorum Group is a clinical-stage biopharmaceutical company based in the UK, dedicated to the exploration, development, and commercialization of therapeutic assets for the treatment of diseases with unmet medical needs. |
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023NEW YORK & LONDON, December 22, 2023--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. |
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of ShareholdersNEW YORK & LONDON, December 21, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. |
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023NEW YORK & LONDON, November 16, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2023 annual general meeting of shareholders at its London office located at 17 Hanover Square, Mayfair London, England W1S 1BN at 1:00 p.m. London Time on December 20, 2023 (8:00 a.m. Eastern Standard Time on Decem |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning! |
APM Price Returns
| 1-mo | -36.84% |
| 3-mo | 210.56% |
| 6-mo | 212.29% |
| 1-year | 92.76% |
| 3-year | -78.75% |
| 5-year | -95.93% |
| YTD | 128.29% |
| 2023 | -55.49% |
| 2022 | -63.33% |
| 2021 | -39.27% |
| 2020 | -84.42% |
| 2019 | 4.41% |
Loading social stream, please wait...